Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2010-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00681967
- Locations
- 🇨🇭
Research Site, Bern, Switzerland
Ph II Early BC Pre-Surgical Biologic Study
- Conditions
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00637026
Open Label Trial to Assess Iressa in Prostate Cancer Patients
- Conditions
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00635856
Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 35
- Registration Number
- NCT00616499
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Yonsei Cancer Center at Yonsei University Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2008-02-22
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT00614809
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
- Conditions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 156
- Registration Number
- NCT00608868
- Locations
- 🇰🇷
Research Site, Daegu, Korea, Republic of
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
- Conditions
- Interventions
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00588445
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2013-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT00536107
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
- First Posted Date
- 2007-08-21
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 44
- Registration Number
- NCT00519077
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Iressa Study in Patients With Salivary Gland Cancer
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT00509002
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.